Last reviewed 2026-05-29 · How we verify

Flucam (AMPIROXICAM)

Phase 2 active Small molecule ✓ Verified May 2026

Flucam (generic name: AMPIROXICAM) is a Nonsteroidal Anti-inflammatory Drug drug. It is currently in Phase 2 development.

Flucam works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins that cause pain and inflammation.

Flucam is a small molecule. It has been studied in combination with Fludara and Campath for the treatment of B-Cell Chronic Lymphocytic Leukemia.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AMPIROXICAM
Drug class	Nonsteroidal Anti-inflammatory Drug
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. Flucam blocks these messengers from being made, which helps to reduce pain and inflammation. This is similar to how other NSAIDs, like ibuprofen, work.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flucam CI brief — competitive landscape report
Flucam updates RSS · CI watch RSS

Frequently asked questions about Flucam

What is Flucam?

Flucam (AMPIROXICAM) is a Nonsteroidal Anti-inflammatory Drug drug.

How does Flucam work?

Flucam works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins that cause pain and inflammation.

What is the generic name of Flucam?

AMPIROXICAM is the generic (nonproprietary) name of Flucam.

What drug class is Flucam in?

Flucam belongs to the Nonsteroidal Anti-inflammatory Drug class. See all Nonsteroidal Anti-inflammatory Drug drugs at /class/nonsteroidal-anti-inflammatory-drug.

What development phase is Flucam in?

Flucam is in Phase 2.

Drug class: All Nonsteroidal Anti-inflammatory Drug drugs
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing